Thanks. I'll try to squeeze in my second question.
A group of clinician scientists and patient advocates recently asked the FDA in the United States not to prematurely grant licensure to COVID-19 vaccines that have emergency use authorization right now until they have fulfilled all regulatory requirements, which include biodistribution studies and a minimum two-year follow-up of participants of pivotal trials.
Is that something, in your view, that Health Canada should follow?